Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

Daratumumab is a CD38 monoclonal antibody recently approved for the treatment of multiple myeloma (MM). We report daratumumab pharmacokinetic data from GEN501, a phase I/II dose-escalation (0.005–24 mg/kg) and dose-expansion (8 or 16 mg/kg) study, and SIRIUS, a phase II study (8 or 16 mg/kg), in rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemens, Pamela L., Yan, Xiaoyu, Lokhorst, Henk M., Lonial, Sagar, Losic, Nedjad, Khan, Imran, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Zhou, Honghui, Puchalski, Thomas, Xu, Xu Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511594/
https://www.ncbi.nlm.nih.gov/pubmed/27896689
http://dx.doi.org/10.1007/s40262-016-0477-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511594/
https://www.ncbi.nlm.nih.gov/pubmed/27896689
http://dx.doi.org/10.1007/s40262-016-0477-1

Ejemplares similares